Dilution of Share Value Resulting from the Exercise of Share Acquisition Rights
First written in FY2016. 15 of 35 entries say "Restated". Latest entry: FY2026.
Trenders moved to the "Worse" side of this theme in 2026, 5 years after the typical company in this theme (2021).
The whole theme swung hardest in 2017: 34 of 62 companies on the "Worse" side.
38 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Total number of stock acquisition rights 3,000 rights Class and number of shares underlying the stock acquisition rights Our common shares 300,000 shares」
On 29 May 2026, after the filing, stock acquisition rights representing up to 300,000 shares were allocated to 15 directors and employees of the Company and its subsidiaries. This is a potential source of dilution in addition to the 120,000 shares underlying existing stock acquisition rights at the fiscal year-end. - FY2026-H1Increase in Issued Shares through Exercise of Share Acquisition RightsAnnual report
「1 April 2025–30 September 2025 (Note) 3,000 8,101,000 648,048 322,665 (Note) Increase resulting from the exercise of stock acquisition rights.」
The number of issued shares increased by 3,000 through the exercise of stock acquisition rights between April and September 2025, bringing the total to 8,101,000. - FY2025MitigatedAnnual report
「As of 31 March 2025, the number of shares underlying the stock acquisition rights was 123,000, equivalent to 1.5% of the total 8,098,000 issued shares. If these stock acquisition rights or stock acquisition rights granted in the future are exercised, the value of the Group's shares may be diluted.」
The dilution risk remains, but the number of shares underlying the rights declined from 327,400 in the previous fiscal year to 123,000, and their percentage of total issued shares declined from 4.1% to 1.5%. - FY2025-H1RestatedAnnual report
「During the interim consolidated accounting period, there were no new business or other risks, nor any significant changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2024MitigatedAnnual report
「As of 31 March 2024, the number of shares underlying the stock acquisition rights was 327,400, equivalent to 4.1% of the total 7,992,600 issued shares. If these stock acquisition rights or stock acquisition rights granted in the future are exercised, the value of the Group's shares may be diluted. (*) The Series 5 stock acquisition rights, representing 99,000 underlying shares, expired on the filing date. The remaining stock acquisition rights represented 228,400 underlying shares, equivalent to 2.9% of total issued shares.」
The dilution risk remains, although the Series 5 stock acquisition rights representing 99,000 shares expired on the filing date, reducing the number of remaining shares underlying the rights from 327,400 to 228,400 and their percentage of total issued shares from 4.1% to 2.9%. - FY2024-Q3Increase in Issued Shares through Exercise of Share Acquisition RightsAnnual report
「1 October 2023–31 December 2023 (Note) 1 3,600 7,953,000 (Note) 1. Increase resulting from the exercise of stock acquisition rights.」
The number of issued shares increased by 3,600 through the exercise of stock acquisition rights during the third quarter, bringing the total to 7,953,000. A further 12,600 shares were issued through exercises in January 2024, bringing the total to 7,965,600 as of the filing date. - FY2024-Q2Increase in Issued Shares through Exercise of Share Acquisition RightsAnnual report
「1 July 2023–30 September 2023 (Note) 317,400 7,949,400 53,561 622,466 53,561 297,082 (Note) Increase resulting from the exercise of stock acquisition rights.」
The number of issued shares increased by 317,400 through the exercise of stock acquisition rights during the second quarter, bringing the total to 7,949,400. - FY2024-Q1Increase in Issued Shares through Exercise of Share Acquisition RightsAnnual report
「1 April 2023–30 June 2023 3,200 7,632,000 540 568,905 540 243,521 (Note) Increase resulting from the exercise of stock acquisition rights.」
3,200 shares were issued through the exercise of stock acquisition rights during the first quarter, bringing the total number of issued shares to 7,632,000. - FY2023MitigatedAnnual report
「As of 31 March 2023, the number of shares underlying the stock acquisition rights was 697,200, equivalent to 9.14% of the total 7,628,800 issued shares. If these stock acquisition rights or stock acquisition rights granted in the future are exercised, the value of the Group's shares may be diluted.」
The dilution risk remains, but the number of shares underlying the rights declined from 744,400 in the previous fiscal year to 697,200, and their percentage of total issued shares declined from 9.78% to 9.14%. - FY2023-Q3Increase in Issued Shares through Exercise of Share Acquisition RightsAnnual report
「The total number of issued shares increased by 9,000 through the exercise of stock acquisition rights during the period from 1 January 2023 to 31 January 2023.」
The total number of issued shares increased by 9,000 through the exercise of stock acquisition rights after the end of the quarter, reaching 7,626,400 as of the filing date. - FY2023-Q2Increase in Issued Shares through Exercise of Share Acquisition RightsAnnual report
「1 July 2022– 30 September 2022 (Note) 9,400 7,617,400 (Note) Increase resulting from the exercise of stock acquisition rights.」
9,400 shares were issued through the exercise of stock acquisition rights between July and September 2022, bringing the total number of issued shares to 7,617,400. - FY2023-Q1Increase in Issued Shares through Exercise of Share Acquisition RightsAnnual report
「The total number of issued shares increased by 6,400 through the exercise of stock acquisition rights during the period from 1 July 2022 to 31 July 2022.」
The total number of issued shares increased by 6,400 through the exercise of stock acquisition rights after the end of the quarter, reaching 7,614,400 as of the filing date. - FY2022MitigatedAnnual report
「As of 31 March 2022, the number of shares underlying the stock acquisition rights was 744,400, equivalent to 9.78% of the total 7,608,000 issued shares. If these stock acquisition rights or stock acquisition rights granted in the future are exercised, the value of the Group's shares may be diluted.」
The dilution risk remains, but the number of shares underlying the rights declined from 815,000 in the previous fiscal year to 744,400, and their percentage of total issued shares declined from 10.79% to 9.78%. - FY2022-Q3Increase in Issued Shares through Exercise of Share Acquisition RightsAnnual report
「The increase resulted from the exercise of stock acquisition rights.」
26,400 shares were issued through the exercise of stock acquisition rights between October and December 2021, bringing the total number of issued shares to 7,608,000. - FY2022-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2021MitigatedAnnual report
「As of 31 March 2021, the number of shares underlying the stock acquisition rights was 815,000, equivalent to 10.79% of the total 7,554,000 issued shares. If these stock acquisition rights or stock acquisition rights granted in the future are exercised, the value of the Group's shares may be diluted.」
The dilution risk remains, but the number of shares underlying the rights declined from 972,000 in the previous fiscal year to 815,000, and their percentage of total issued shares declined from 13.03% to 10.79%. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter of the current fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the previous fiscal year’s annual securities report.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter of the current fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the previous fiscal year’s annual securities report.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2020Increase in number of shares; decline in percentageAnnual report
「As of 31 March 2020, the number of shares underlying the stock acquisition rights was 972,000, equivalent to 13.03% of the total 7,460,400 issued shares. If these stock acquisition rights or stock acquisition rights granted in the future are exercised, the value of the Group's shares may be diluted.」
The number of shares subject to potential dilution increased from 563,900 to 972,000, while their percentage of total issued shares declined from 15.15% to 13.03%, with the two risk indicators moving in opposite directions. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter of the current fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the previous fiscal year’s annual securities report.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter of the current fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the previous fiscal year’s annual securities report.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2020-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter of the current fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the previous fiscal year’s annual securities report.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter of the current fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the previous fiscal year’s annual securities report.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2019-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2018WorsenedAnnual report
「As of 31 March 2018, the number of shares underlying the stock acquisition rights was 563,900, equivalent to 15.15% of the total 3,721,800 issued shares. If these stock acquisition rights or stock acquisition rights granted in the future are exercised, the value of our shares may be diluted.」
The number of shares subject to potential dilution increased from 461,200 to 563,900, and their percentage of total issued shares increased from 12.52% to 15.15%. - FY2018-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2018-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2018-Q1RestatedAnnual report
「During the three months ended March, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2017MitigatedAnnual report
「As of 31 March 2017, the number of shares underlying the stock acquisition rights was 461,200, equivalent to 12.52% of the total 3,684,000 issued shares. If these stock acquisition rights or stock acquisition rights granted in the future are exercised, the value of our shares may be diluted.」
The dilution risk remains, but the number of shares underlying the rights declined from the previously disclosed 498,600 to 461,200, and their percentage of total issued shares declined from 13.65% to 12.52%. - FY2017-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2017-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights. - FY2016First statedAnnual report
「As of 31 March 2016, the number of shares underlying the stock acquisition rights was 498,600, equivalent to 13.65% of the total 3,651,600 issued shares. If these stock acquisition rights or stock acquisition rights granted in the future are exercised, the value of our shares may be diluted.」
The disclosure shows the number of shares underlying the stock acquisition rights and their percentage of issued shares, and identifies dilution upon exercise as a risk.